Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03173300 · ClinicalTrials.gov registry record
Natural History Study Protocol in PMM2-CDG (CDG-Ia)
A clinical trial of Phosphomannomutase 2 Deficiency, sponsored by Glycomine.
- Active
- Registry status
- 120
- Enrollment target
- 11
- Study locations
NCT03173300 is a study of Phosphomannomutase 2 Deficiency that is active but no longer recruiting, run by Glycomine. The registered enrollment target is 120 participants. The trial reports 11 study locations across 5 states.
The verdict
NCT03173300, a study of Phosphomannomutase 2 Deficiency, is active but no longer recruiting, sponsored by Glycomine.
- ACTIVE NOT RECRUITING
- Registry status
- 120 participants
- Enrollment target
- 11
- Study locations
Study Summary
Clinical and Basic Investigations into Phosphomannomutase deficiency (PMM2-CDG) This is a natural history (observational) protocol designed to collect clinical and biological information in patients with PMM2-CDG (CDG-Ia).
Conditions Studied
Study Locations (11)
Other
- General University Hospital in Prague - Prague
- Necker Enfants-Malades Hospital - Paris
- University Hospital of Catania - Catania
- Radboud University Nejmegen Medical Center - Nijmegen
- Mother and Child Institute (Instytut Matki i Dziecka) - Warsaw
- Centro Hospitalar do Porto - Porto
- Hospital Sant Joan de Déu - Barcelona
Minnesota
- Mayo Clinic College of Medicine - Rochester
Pennsylvania
- Children's Hospital of Philadelphia (CHOP) - Philadelphia
Washington
- Seattle Children's Hospital - Seattle
Belgium
- University Hospital Leuven - Leuven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2018-01-08 |
| Est. Completion | 2026-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03173300
The ClinicalTrials.gov registry entry for NCT03173300 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Glycomine, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Phosphomannomutase 2 Deficiency appearing as the primary indexed condition, and to 0 interventions.
NCT03173300 reports 11 study locations spanning 5 distinct geographic areas - top geographies include Other, Minnesota, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03173300 about?
NCT03173300 is a clinical study titled "Natural History Study Protocol in PMM2-CDG (CDG-Ia)". Clinical and Basic Investigations into Phosphomannomutase deficiency (PMM2-CDG) This is a natural history (observational) protocol designed to collect clinical and biological information in patients with PMM2-CDG (CDG-Ia).
What is the current status of trial NCT03173300?
This trial is currently active not recruiting. The enrollment target is 120 participants. The study started on 2018-01-08. Estimated completion is 2026-03.
What conditions does trial NCT03173300 study?
This clinical trial studies the following conditions: Phosphomannomutase 2 Deficiency.
Who is sponsoring clinical trial NCT03173300?
This trial is sponsored by Glycomine, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03173300 being conducted?
This trial has 11 study locations across Minnesota, Pennsylvania, Washington, Belgium. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Phosphomannomutase 2 Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.